Page last updated: 2024-08-24

mk 0591 and Bronchopulmonary Dysplasia

mk 0591 has been researched along with Bronchopulmonary Dysplasia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kim, KE; Lee, C; Namgung, R; Park, MS; Sohn, MH	1

Other Studies

1 other study(ies) available for mk 0591 and Bronchopulmonary Dysplasia

Article	Year
5-Lipoxygenase-activating protein (FLAP) inhibitor MK-0591 prevents aberrant alveolarization in newborn mice exposed to 85% oxygen in a dose- and time-dependent manner. Lung, 2011, Volume: 189, Issue:1 Topics: 5-Lipoxygenase-Activating Protein Inhibitors; 5-Lipoxygenase-Activating Proteins; Animals; Animals, Newborn; Body Weight; Bronchopulmonary Dysplasia; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hyperoxia; Indoles; Infant, Newborn; Injections, Subcutaneous; Mice; Oxygen; Pulmonary Alveoli; Quinolines; Time Factors	2011

Article

Year

5-Lipoxygenase-activating protein (FLAP) inhibitor MK-0591 prevents aberrant alveolarization in newborn mice exposed to 85% oxygen in a dose- and time-dependent manner.

Lung, 2011, Volume: 189, Issue:1

Topics: 5-Lipoxygenase-Activating Protein Inhibitors; 5-Lipoxygenase-Activating Proteins; Animals; Animals, Newborn; Body Weight; Bronchopulmonary Dysplasia; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hyperoxia; Indoles; Infant, Newborn; Injections, Subcutaneous; Mice; Oxygen; Pulmonary Alveoli; Quinolines; Time Factors

2011